Barcelona – Pittsburgh

Professor of Neurology at the National and Kapodistrian University of Athens, with academic affiliation at Columbia University. His research focuses on cognitive reserve and lifestyle factors, including diet, in Alzheimer’s disease and aging.

Clifford R. Jack Jr., M.D. is Professor of Radiology (Neuroradiology) and the Alexander Family Professor of Alzheimer’s Disease Research at Mayo Clinic in Rochester MN.

The speaker’s biography is currently being reviewed and will be published soon.

Distinguished Professor of Neurology and Neuroscience at the University of Yaoundé I, he is a leading figure in clinical and research leadership in Africa. Founder of the Brain Research Africa Initiative (BRAIN), his work focuses on neurodegeneration, epilepsy, and translational neuroscience. With over 230 publications, his contributions include advances in onchocerciasis-associated epilepsy and the development of the Actigraphic Sleep Score.

Dr. Wepnyu Yembe Njamnshi is a physician–scientist specializing in neuropsychology and brain health in Africa, and Director of Operations at BRAIN Cameroon. He leads major initiatives in dementia research, including the BUILD-FSA programme and the Cameroon National Dementia Plan Project. His work focuses on strengthening research capacity and advancing innovative solutions across the continent.

Associate Professor of Bioinformatics at the Glenn Biggs Institute for Alzheimer’s & Neurodegenerative Diseases, within the Department of Biochemistry and Structural Biology at UT Health San Antonio, USA. He also serves as Program Director of the African Initiative for Bioinformatics Online Training in Neurodegenerative Diseases (AI-BOND).

His research focuses on the intersection of artificial intelligence and healthcare, developing advanced methods in biomedical machine vision, multimodal learning, and generalist AI to support clinical decision-making.
He is a Senior Member of IEEE and Fellow of the American Heart Association, with work funded by major institutions including NIH and Gates Ventures

Laia Montoliu-Gaya, PhD, Assistant Professor at University of Gothenburg

Director del Centre d’Esclerosi Múltiple de Catalunya (Cemcat) a l’Hospital Universitari Vall d’Hebron i cap del Grup de Recerca en Neuroimmunologia de l’Institut de Recerca Vall d’Hebron.

At Ace, he design CTs and other global CT from pharmaceutical companies, participate in international boards to improve CT management and promote research projects to validate novel biomarkers for an early detection of the disease and find novel therapeutical approaches.

Bruno Vellas is a leading expert in geriatrics and healthy aging, founder of major international initiatives such as EADC, CTAD, and ICFSR.

Prof. Heneka is involved in basic science and translational research with focus on neurodegeneration and neuroinflammation.

Dr. Boada focuses her research on the treatment of AD and related dementias, especially on the genotype and phenotype of common degenerative diseases and the design of new pharmacological and non-pharmacological treatments.

Dr. Cano is in charge of the molecular biology unit of Ace Alzheimer Center Barcelona and her studies are related to the clinical evaluation of early biomarkers of Alzheimer’s disease.

The main objective of his genomic research group is to understand the causes of Alzheimer’s disease and other dementias by integrating genetic, transcriptomic and proteomic data.

He has more than 20 years of experience in basic, clinical and applied research in drug dependence, psychopathology and memory disorders.

Dr. Villemagne is a physician–scientist and Tenured Professor specializing in the development of molecular biomarkers for the discovery, diagnosis, prognosis, and clinical trials of neurodegenerative diseases.